NCT05873283

Brief Summary

Papillary cancer is a disease that spreads through lymphatic ways and its treatment is surgery. We performed prophylactic central dissection in addition to bilateral total thyroidectomy in patients with bethesda 5 and bethesda 6 biopsy results. We evaluated the pathology results retrospectively.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 12, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2022

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 24, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 15, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 24, 2023

Completed
Last Updated

May 24, 2023

Status Verified

May 1, 2023

Enrollment Period

1.6 years

First QC Date

May 15, 2023

Last Update Submit

May 15, 2023

Conditions

Papillary Thyroid Cancer

Keywords

papillary thyroid cancer

Outcome Measures

Primary Outcomes (1)

  • Reaching 100 patients was the first target

    100 patients

    18 months

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with B5 and B6 biopsy results who underwent bilateral total thyroidectomy and central lymph node dissection

You may qualify if:

  • \- B5 and B6 biopsy results

You may not qualify if:

  • \- lobectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BasaksehirCamSakuraSehirH

Istanbul, Turkey (Türkiye)

Location

Related Publications (1)

  • Ozel TM, Soytas Y, Akbulut S, Celik A, Yildiz G, Karatay H, Sari S. The necessity of prophylactic central lymph node dissection in clinically n0 papillary thyroid carcinoma: perspective from the endemic region. Langenbecks Arch Surg. 2025 Mar 28;410(1):109. doi: 10.1007/s00423-025-03667-y.

    PMID: 40153045DERIVED

MeSH Terms

Conditions

Thyroid Cancer, Papillary

Condition Hierarchy (Ancestors)

Adenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsThyroid NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 15, 2023

First Posted

May 24, 2023

Study Start

June 12, 2020

Primary Completion

February 1, 2022

Study Completion

March 24, 2023

Last Updated

May 24, 2023

Record last verified: 2023-05

Locations

TU(1)